Nouh Ahmed Hassan, Behairy Ayaat Abd Elghany, El-Koumy Fatma Badr, Aal Ahmed Mohamed Abdel, Zhuravlova Maryna S
Department of Dermatology, Venereology, and Andrology, Al-Azhar University, Cairo, Egypt.
Faculty of Medicine of Al-Azhar university, Cairo, Egypt.
Arch Dermatol Res. 2025 Apr 19;317(1):723. doi: 10.1007/s00403-025-04183-1.
Alopecia Areata (AA) is a chronic, immune-mediated inflammatory condition primarily targeting hair follicles, leading to non-scarring hair loss. Traditional therapeutic approaches, including topical and systemic immunosuppressive treatments, often yield inconsistent results and carry significant side effects. Recently, laser therapy has emerged as a promising modality for AA treatment, particularly when combined with adjunctive agents that enhance hair follicle stimulation. This study evaluates the efficacy and safety of a novel therapeutic combination: CO2 fractional laser therapy with Bimatoprost 0.03% solution application. Conducted at Al-Azhar University Hospital between January 2019 and May 2023, the study involved 60 patients with clinically and dermoscopically confirmed AA. Participants were randomly assigned into two groups: Group A (n = 30) received three CO2 fractional laser sessions with subsequent daily application of Bimatoprost 0.03%, while Group B (n = 30) underwent laser therapy alone. Clinical outcomes were assessed using standardized photographic documentation, dermoscopic evaluation, and patient-reported improvement scores. Results demonstrated a significantly higher response rate in Group A compared to Group B (80% vs. 40%, p = 0.025). The combination therapy led to faster and more pronounced hair regrowth, with notable improvements in hair density, pigmentation, and thickness. Minimal adverse effects were reported, limited to transient erythema and mild procedural discomfort. Statistical analysis confirmed a superior treatment response in Group A across all assessment parameters (p < 0.05). These findings suggest that the combination of CO2 fractional laser therapy with Bimatoprost 0.03% offers a safe and effective treatment modality for AA, outperforming laser therapy alone. This study provides a foundation for further research and highlights the potential integration of prostaglandin analogs with laser-based interventions in AA management. Future studies with larger sample sizes and extended follow-up periods are necessary to validate these promising results and assess long-term treatment sustainability.
斑秃（AA）是一种慢性、免疫介导的炎症性疾病，主要侵袭毛囊，导致非瘢痕性脱发。传统的治疗方法，包括局部和全身免疫抑制治疗，往往效果不一且伴有严重的副作用。近年来，激光治疗已成为一种有前景的斑秃治疗方式，尤其是与增强毛囊刺激的辅助药物联合使用时。本研究评估了一种新型治疗组合的疗效和安全性：二氧化碳点阵激光联合0.03%比马前列素溶液治疗。该研究于2019年1月至2023年5月在爱资哈尔大学医院进行，纳入了60例经临床和皮肤镜确诊的斑秃患者。参与者被随机分为两组：A组（n = 30）接受三次二氧化碳点阵激光治疗，随后每天使用0.03%比马前列素，而B组（n = 30）仅接受激光治疗。使用标准化的照片记录、皮肤镜评估和患者报告的改善评分来评估临床结果。结果显示，A组的有效率显著高于B组（80%对40%，p = 0.025）。联合治疗导致头发生长更快、更明显，在头发密度、色素沉着和厚度方面有显著改善。报告的不良反应最小，仅限于短暂的红斑和轻微的操作不适。统计分析证实，A组在所有评估参数上的治疗反应均优于B组（p < 0.05）。这些发现表明，二氧化碳点阵激光联合0.03%比马前列素为斑秃提供了一种安全有效的治疗方式，优于单纯激光治疗。本研究为进一步研究奠定了基础，并突出了前列腺素类似物与基于激光的干预措施在斑秃管理中的潜在整合。未来需要更大样本量和更长随访期的研究来验证这些有前景的结果，并评估长期治疗的可持续性。
